VCH 916

Drug Profile

VCH 916

Alternative Names: VCH-916

Latest Information Update: 07 Apr 2011

Price : $50

At a glance

  • Originator Shire
  • Developer Vertex Pharmaceuticals
  • Class Antivirals; Small molecules
  • Mechanism of Action Hepatitis C virus NS 5 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Hepatitis C

Most Recent Events

  • 31 Dec 2010 Discontinued - Phase-I/II for Hepatitis C in Canada (PO)
  • 31 Dec 2010 Discontinued - Phase-I/II for Hepatitis C in Puerto Rico (PO)
  • 31 Dec 2010 Discontinued - Phase-I/II for Hepatitis C in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top